Reaction

Infection Susceptibility Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,157 reports · 45 co-occurring drugs

As of the last recalculation, Infection Susceptibility Increased appears in 2,157 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is CIMETIDINE (PRR 58.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Cimetidine	57	58.6	59.0
Acetylcysteine	44	46.0	46.2
Memantine	56	40.5	40.7
Memantine Hydrochloride	56	40.5	40.7
Anakinra	57	34.0	34.1
Lithium Carbonate	51	29.7	29.7
Diltiazem Hydrochloride Extended-Release Tablets	34	29.3	29.4
Bumetanide	58	21.7	21.8
Amitriptyline Hydrochloride	37	20.7	20.7
Ocrelizumab	119	19.5	19.6
Diroximel Fumarate	16	13.0	13.1
Clonidine	59	11.4	11.4
Diltiazem Hydrochloride	38	10.8	10.8
Adalimumab-Aaty	48	10.0	10.0
Lidocaine Hydrochloride	59	9.7	9.7
Canakinumab	10	9.0	9.0
Adalimumab-Fkjp	41	8.7	8.7
Adalimumab-Adaz	45	8.4	8.4
Montelukast	69	8.2	8.2
Hydroxychloroquine Sulfate	67	7.3	7.3
Carfilzomib	21	7.2	7.2
Peginterferon Beta-1A	9	6.6	6.7
Tofacitinib Citrate	9	6.6	6.7
Upadacitinib	50	6.0	6.0
Atovaquone	5	6.0	6.0
Metoroprolol Tartrate	40	5.9	5.9
Ezetimibe	45	5.9	5.9
Dimethyl Fumarate	73	5.9	5.9
Ofatumumab	18	5.3	5.3
Fingolimod Hcl	41	4.6	4.6
Apremilast	65	4.4	4.4
Natalizumab	79	4.3	4.3
Avapritinib	5	4.0	4.0
Venetoclax	24	3.8	3.8
Secukinumab	62	3.8	3.8
Tofacitinib	70	3.8	3.8
Azacitidine For	7	3.7	3.7
Etanercept	209	3.6	3.6
Risankizumab-Rzaa	28	3.3	3.3
Bendamustine Hydrochloride	4	3.2	3.2
Ruxolitinib	23	3.1	3.1
Daratumumab	12	2.9	2.9
Paliperidone	7	2.9	2.9
Glatiramer Acetate	17	2.8	2.8
Dalfampridine	18	2.4	2.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.